Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
|ClinicalTrials.gov Identifier: NCT00976248|
Recruitment Status : Active, not recruiting
First Posted : September 14, 2009
Results First Posted : June 16, 2014
Last Update Posted : October 12, 2017
|Condition or disease||Intervention/treatment||Phase|
|Waldenstrom's Macroglobulinemia||Drug: RAD001||Phase 2|
- Participants will take RAD001 orally once a day in the morning. Each treatment cycle lasts for four weeks. Participants will receive up to 72 cycles of treatment.
- During each cycle, participants will be asked to visit the clinic for scheduled tests and exams. They will visit the clinic on the first day of each of the first three cycles, and then once every 3 cycles. During the visits, participants will have a physical exam and blood tests.. Participants may also have CT scans of the chest, abdomen and pelvis as well as a bone marrow aspirate and biopsy.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||33 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia|
|Study Start Date :||November 2009|
|Actual Primary Completion Date :||July 2016|
|Estimated Study Completion Date :||July 2018|
U.S. FDA Resources
RAD001, oral, 10 mg, daily
Taken orally once a day
Other Name: Everolimus
- Overall Response Rate of RAD001 in Patients With Previously Untreated WM [ Time Frame: End of Treatment, an average of 16 months ]
Overall Response = Complete Response + Near Complete Response + Very Good Partial Response + Partial Response + Minor Response Complete Response: resolution of all symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly. A near CR (nCR) is defined as fulfilling all CR criteria in the presence of positive immunofixation test for an IgM paraprotein.
Very Good Partial Response: > 90% reduction in serum IgM levels. Partial Response: > 50% reduction in serum IgM levels. Minor Response: 25-49% reduction in serum IgM levels Progressive Disease: greater than 25% increase in serum IgM level occurs from the lowest attained response value or progression of clinically significant disease related symptom(s).
Stable Disease: < 25% change in serum IgM levels, in the absence of new or increasing adenopathy or splenomegaly and/or other progressive signs or symptoms of WM
- Time to Progression With Single Agent RAD001 Therapy in Previously Untreated WM. [ Time Frame: End of Treatment, an average of 16 months ]Progression is defined as a 25% increase in serum IgM from the lowest attained response value or progression of clinically significant disease related symptoms.
- Time to Next Therapy With Single Agent RAD001 Therapy in Previously Untreated WM [ Time Frame: End of follow-up, an average of 18 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00976248
|United States, Massachusetts|
|Dana-Farber Cancer Institute|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Steven Treon, MD||Dana-Farber Cancer Institute|